How big is the New Zealand Oral Anti-Diabetic Drug Market?

The New Zealand Oral Anti-Diabetic Drug Market size is expected to reach USD 323 million in 2024 and grow at a CAGR of 2.60% to reach USD 367.23 million by 2029. Read More

What is the current New Zealand Oral Anti-Diabetic Drug Market size?

In 2024, the New Zealand Oral Anti-Diabetic Drug Market size is expected to reach USD 323 million. Read More

Who are the key players in New Zealand Oral Anti-Diabetic Drug Market?

Astellas Pharma Inc., AstraZeneca, Sanofi, Eli Lilly and Company and Janssen Pharmaceuticals are the major companies operating in the New Zealand Oral Anti-Diabetic Drug Market. Read More

What years does this New Zealand Oral Anti-Diabetic Drug Market cover, and what was the market size in 2023?

In 2023, the New Zealand Oral Anti-Diabetic Drug Market size was estimated at USD 314.60 million. The report covers the New Zealand Oral Anti-Diabetic Drug Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the New Zealand Oral Anti-Diabetic Drug Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

New Zealand Oral Anti-Diabetic Drug Market Share

Statistics for the 2023 & 2024 New Zealand Oral Anti-Diabetic Drug market share, created by Mordor Intelligence™ Industry Reports. New Zealand Oral Anti-Diabetic Drug share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of New Zealand Oral Anti-Diabetic Drug Industry

New Zealand's oral anti-diabetes drug market is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global presence. The remaining manufacturers are confined to other local or regional markets. Companies are focusing on innovations in diabetes drugs.